EMA Authorised: Braftovi (Encorafenib) — Pierre Fabre Medicament

View source ↗

Summary

The EMA authorises Braftovi (encorafenib) for melanoma and colorectal neoplasms.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Neoplasms
• Melanoma

Drugs mentioned

• BRAFTOVI (ENCORAFENIB)

Snippet

Status: Authorised. Therapeutic area: Melanoma;Colorectal Neoplasms. MAH: Pierre Fabre Medicament. Decision date: 19/06/2026